Goldman Sachs analyst Keyur Parekh reiterated a Sell rating on AstraZeneca (NASDAQ: AZN) after the company announced positive results from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE